UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~September 293, 2025

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales		001-730430		98-1795578
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

23 Old Bond Street, Floor 3

London, W1S 4PZ

England, United Kingdom

(Address of principal executive offices, including zip code)

(781) 431-9100

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Ordinary Shares, $0.000273235 nominal value	KNSA	The Nasdaq Stock Market LLC
		(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2 7.0201. ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On ~~July 29~~September 3, 2025, Kiniksa Pharmaceuticals International, plc ~~issued~~(the a“Company”) ~~press~~posted ~~release~~an ~~announcing~~investor ~~financial~~presentation ~~results for~~ (the ~~quarter~~“Investor ~~ended~~Presentation”) ~~June~~to ~~30,~~its ~~2025~~website at investors.kiniksa.com. AThe ~~copy~~Company ofexpects to use the ~~press~~Investor ~~release~~Presentation, in whole or in part, and possibly with modifications, isin ~~furnished~~connection with ~~this~~its ~~Current~~planned ~~Report~~presentations onto ~~Form 8-K~~investors, asanalysts ~~Exhibit 99~~and others.1.

A copy of the Investor Presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		~~Earnings Press Release issued by~~ Kiniksa Pharmaceuticals International, plc, ~~dated~~Investor ~~July 29, 2025~~Presentation
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: July 29, 2025	By:	/s/ Madelyn Zeylikman
Date: September 3, 2025	By:	/s/ Mark Ragosa
		Madelyn Zeylikman
		Mark Ragosa
		Senior Vice President, General Counsel and Secretary
		Executive Vice President, Chief Financial Officer

Filing Compare · Kiniksa Pharmaceuticals International, plc